In the present study, we were able to functionalize TuMV VLPs with antibodies targeted specifically towards EGFR, which would increase their performance in a tumor environment as they will not only have a good tumor-homing ability but also a high affinity and attachment to cells overexpressing this receptor. The gene discussed is EGFR; the disease is neoplasm.